Personal information

Activities

Works (50 of 61)

Items per page:
Page 1 of 2

Exploring Patient Preference Information in Clinical Research and Decision Models: An Investigative Survey

2024-12-27 | Preprint
Contributors: Martina Di Blasio; Zahra Bami; Carmen Fava; Alessia Visconti; Ileana Baldi; Paola Berchialla
Source: check_circle
Crossref

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

Leukemia
2020-08 | Journal article
Contributors: Massimo Breccia; Elisabetta Abruzzese; Monica Bocchia; Massimiliano Bonifacio; Fausto Castagnetti; Carmen Fava; Sara Galimberti; Antonella Gozzini; Gabriele Gugliotta; Alessandra Iurlo et al.
Source: check_circle
Crossref

Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells

Journal of Clinical Medicine
2019-07-04 | Journal article
Contributors: Valentina Rosso; Cristina Panuzzo; Jessica Petiti; Sonia Carturan; Matteo Dragani; Giacomo Andreani; Carmen Fava; Giuseppe Saglio; Enrico Bracco; Daniela Cilloni
Source: check_circle
Crossref

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome

British Journal of Haematology
2018 | Journal article
EID:

2-s2.0-85012870961

Contributors: Sora, F.; Iurlo, A.; Sica, S.; Latagliata, R.; Annunziata, M.; Galimberti, S.; Castagnetti, F.; Pregno, P.; Sgherza, N.; Celesti, F. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

Annals of Hematology
2018 | Journal article
EID:

2-s2.0-85039838668

Contributors: Iurlo, A.; Galimberti, S.; Abruzzese, E.; Annunziata, M.; Bonifacio, M.; Latagliata, R.; Pregno, P.; Ferrero, D.; Sorà, F.; Orlandi, E.M. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Residual peripheral blood CD26<sup>+</sup>leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission

Frontiers in Oncology
2018 | Journal article
EID:

2-s2.0-85047827251

Contributors: Bocchia, M.; Sicuranza, A.; Abruzzese, E.; Iurlo, A.; Sirianni, S.; Gozzini, A.; Galimberti, S.; Aprile, L.; Martino, B.; Pregno, P. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia

Cancer Chemotherapy and Pharmacology
2017 | Journal article
EID:

2-s2.0-85015078732

Contributors: Galeotti, L.; Ceccherini, F.; Domingo, D.; Laurino, M.; Polillo, M.; Di Paolo, A.; Baratè, C.; Fava, C.; D’Avolio, A.; Cervetti, G. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

American Journal of Hematology
2017 | Journal article
EID:

2-s2.0-85019754981

Contributors: Castagnetti, F.; Gugliotta, G.; Breccia, M.; Iurlo, A.; Levato, L.; Albano, F.; Vigneri, P.; Abruzzese, E.; Rossi, G.; Rupoli, S. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia

Oncotarget
2017 | Journal article
EID:

2-s2.0-85031718781

Contributors: Galimberti, S.; Bucelli, C.; Arrigoni, E.; Baratè, C.; Grassi, S.; Ricci, F.; Guerrini, F.; Ciabatti, E.; Fava, C.; D'Avolio, A. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

What should frontline treatment be in chronic myeloid leukemia?

Clinical Advances in Hematology and Oncology
2017 | Journal article
EID:

2-s2.0-85019113455

Contributors: Lee, S.; Fava, C.; Lipton, J.H.; Saglio, G.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

BCR-ABL1 mutation ponatinib resistance

Blood
2016 | Journal article
EID:

2-s2.0-84959449318

Contributors: Saglio, G.; Fava, C.
Source: Self-asserted source
carmen fava via Scopus - Elsevier
grade
Preferred source (of 2)‎

Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor

Clinical Lymphoma, Myeloma and Leukemia
2016 | Journal article
EID:

2-s2.0-84964653273

Contributors: Fava, C.; Rege-Cambrin, G.; Dogliotti, I.; Gottardi, E.; Berchialla, P.; Di Gioacchino, B.; Crasto, F.; Lorenzatti, R.; Volpengo, A.; Daraio, F. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

Neoplasia (United States)
2016 | Journal article
EID:

2-s2.0-84992402708

Contributors: Latagliata, R.; Stagno, F.; Annunziata, M.; Abruzzese, E.; Iurlo, A.; Guarini, A.; Fava, C.; Gozzini, A.; Bonifacio, M.; Sorà, F. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome

Oncotarget
2016 | Journal article
EID:

2-s2.0-84998794985

Contributors: Iurlo, A.; Nobili, A.; Latagliata, R.; Bucelli, C.; Castagnetti, F.; Breccia, M.; Abruzzese, E.; Cattaneo, D.; Fava, C.; Ferrero, D. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Ponatinib for chronic myeloid leukaemia: Future perspectives

The Lancet Oncology
2016 | Journal article
EID:

2-s2.0-84964334374

Contributors: Fava, C.; Saglio, G.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

The choice of first-line chronic myelogenous leukemia treatment

Hematologic Malignancies
2016 | Book
EID:

2-s2.0-85029214377

Contributors: Fava, C.; Rege-Cambrin, G.; Dogliotti, I.; Saglio, G.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia

Annals of Hematology
2016 | Journal article
EID:

2-s2.0-84955177897

Contributors: Efficace, F.; Rosti, G.; Breccia, M.; Cottone, F.; Giesinger, J.M.; Stagno, F.; Iurlo, A.; Russo Rossi, A.; Luciano, L.; Martino, B. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Unleashing the guardian: The targetable BCR-ABL/HAUSP/PML/PTEN network in chronic myeloid leukemia

Current Drug Targets
2016 | Journal article
EID:

2-s2.0-85010680268

Contributors: Morotti, A.; Torti, D.; Carr�, G.; Panuzzo, C.; Crivellaro, S.; Taulli, R.; Fava, C.; Guerrasio, A.; Saglio, G.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

BCR-ABL inactivates cytosolic PTEN through casein kinase II mediated tail phosphorylation

Cell Cycle
2015 | Journal article
EID:

2-s2.0-84928138185

Contributors: Morotti, A.; Panuzzo, C.; Crivellaro, S.; Carrà, G.; Fava, C.; Guerrasio, A.; Pandolfi, P.P.; Saglio, G.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Differences among young adults, adults and elderly chronic myeloid leukemia patients

Annals of Oncology
2015 | Journal article
EID:

2-s2.0-84922503933

Contributors: Castagnetti, F.; Gugliotta, G.; Baccarani, M.; Breccia, M.; Specchia, G.; Levato, L.; Abruzzese, E.; Rossi, G.; Iurlo, A.; Martino, B. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

Haematologica
2015 | Journal article
EID:

2-s2.0-84940914196

Contributors: Gugliotta, G.; Castagnetti, F.; Breccia, M.; Levato, L.; D’Adda, M.; Stagno, F.; Tiribelli, M.; Salvucci, M.; Fava, C.; Martino, B. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Milestones and Monitoring

Current Hematologic Malignancy Reports
2015 | Journal article
EID:

2-s2.0-84929943526

Contributors: Morotti, A.; Fava, C.; Saglio, G.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Recommendations for the management of CML in the era of second-generation TKIs

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia
2015 | Book
EID:

2-s2.0-84957657080

Contributors: Morotti, A.; Fava, C.; Saglio, G.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

The choice of first-line Chronic Myelogenous Leukemia treatment

Annals of Hematology
2015 | Journal article
EID:

2-s2.0-84925936965

Contributors: Fava, C.; Rege-Cambrin, G.; Saglio, G.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Update on emerging treatments for chronic myeloid leukemia

Expert Opinion on Emerging Drugs
2015 | Journal article
EID:

2-s2.0-84930030402

Contributors: Fava, C.; Morotti, A.; Dogliotti, I.; Saglio, G.; Rege-Cambrin, G.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Erratum: Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia (Blood (2013) 121:26 (5138-5144))

Blood
2014 | Journal article
EID:

2-s2.0-84900411268

Contributors: Russo, D.; Martinelli, G.; Malagola, M.; Skert, C.; Soverini, S.; Iacobucci, I.; De Vivo, A.; Testoni, N.; Castagnetti, F.; Gugliotta, G. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia

Expert Opinion on Biological Therapy
2014 | Journal article
EID:

2-s2.0-84894137406

Contributors: Morotti, A.; Panuzzo, C.; Fava, C.; Saglio, G.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia

Therapeutic Drug Monitoring
2014 | Journal article
EID:

2-s2.0-84901449623

Contributors: De Francia, S.; D'Avolio, A.; Ariaudo, A.; Pirro, E.; Piccione, F.; Simiele, M.; Fava, C.; Calcagno, A.; Di Perri, G.; Saglio, G.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Advances in the treatment of chronic myeloid leukemia

Advances in the Treatment of Chronic Myeloid Leukemia
2013 | Book
EID:

2-s2.0-84957059419

Contributors: Saglio, G.; Fava, C.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib

Leukemia
2013 | Journal article
EID:

2-s2.0-84880278964

Contributors: Efficace, F.; Baccarani, M.; Breccia, M.; Cottone, F.; Alimena, G.; Deliliers, G.L.; Baratè, C.; Specchia, G.; Di Lorenzo, R.; Luciano, L. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

Blood
2013 | Journal article
EID:

2-s2.0-84884193097

Contributors: Russo, D.; Martinelli, G.; Malagola, M.; Skert, C.; Soverini, S.; Iacobucci, I.; De Vivo, A.; Testoni, N.; Castagnetti, F.; Gugliotta, G. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Foreword: Advances in the treatment of chronic myeloid leukemia

Advances in the Treatment of Chronic Myeloid Leukemia
2013 | Book
EID:

2-s2.0-84957049007

Contributors: Saglio, G.; Fava, C.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study

Drugs and Aging
2013 | Journal article
EID:

2-s2.0-84880850549

Contributors: Latagliata, R.; Ferrero, D.; Iurlo, A.; Cavazzini, F.; Castagnetti, F.; Abruzzese, E.; Fava, C.; Breccia, M.; Annunziata, M.; Stagno, F. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

Annals of Hematology
2013 | Journal article
EID:

2-s2.0-84872284681

Contributors: Tiribelli, M.; Latagliata, R.; Luciano, L.; Castagnetti, F.; Gozzini, A.; Cambrin, G.R.; Annunziata, M.; Stagno, F.; Pregno, P.; Albano, F. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

Hematological Oncology
2013 | Journal article
EID:

2-s2.0-84878972606

Contributors: Latagliata, R.; Breccia, M.; Fava, C.; Stagno, F.; Tiribelli, M.; Luciano, L.; Gozzini, A.; Gugliotta, G.; Annunziata, M.; Cavazzini, F. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

Haematologica
2013 | Journal article
EID:

2-s2.0-84874514362

Contributors: Rossi, A.R.; Breccia, M.; Abruzzese, E.; Castagnetti, F.; Luciano, L.; Gozzini, A.; Annunziata, M.; Martino, B.; Stagno, F.; Cavazzini, F. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant

Clinical Lymphoma, Myeloma and Leukemia
2013 | Journal article
EID:

2-s2.0-84889058902

Contributors: Fava, C.; Rege-Cambrin, G.; Busca, A.; Gottardi, E.; Daraio, F.; Saglio, G.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Chronic myeloid leukemia: State of the art in 2012

Current Oncology Reports
2012 | Journal article
EID:

2-s2.0-84870569619

Contributors: Fava, C.; Rege-Cambrin, G.; Saglio, G.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)

Journal of Pharmaceutical and Biomedical Analysis
2012 | Journal article
EID:

2-s2.0-82255179202

Contributors: D'Avolio, A.; Simiele, M.; De Francia, S.; Ariaudo, A.; Baietto, L.; Cusato, J.; Fava, C.; Saglio, G.; Di Carlo, F.; Di Perri, G.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Molecular resistance: An early indicator for treatment change?

Clinical Lymphoma, Myeloma and Leukemia
2012 | Journal article
EID:

2-s2.0-84858963632

Contributors: Fava, C.; Kantarjian, H.; Cortes, J.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Practical monitoring of chronic myelogenous leukemia: When to change treatment

JNCCN Journal of the National Comprehensive Cancer Network
2012 | Journal article
EID:

2-s2.0-84855848354

Contributors: Saglio, G.; Fava, C.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients

Journal of Chromatographic Science
2011 | Journal article
EID:

2-s2.0-81455139201

Contributors: Pirro, E.; De Francia, S.; De Martino, F.; Fava, C.; Ulisciani, S.; Cambrin, G.R.; Racca, S.; Saglio, G.; Di Carlo, F.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

Haematologica
2011 | Journal article
EID:

2-s2.0-80053634632

Contributors: Breccia, M.; Latagliata, R.; Stagno, F.; Luciano, L.; Gozzini, A.; Castagnetti, F.; Fava, C.; Cavazzini, F.; Annunziata, M.; Rossi, A.R. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Concomitant occurrence of BCR-ABL and JAK2V617F mutation

Blood
2011 | Journal article
EID:

2-s2.0-80053181285

Contributors: Pieri, L.; Spolverini, A.; Scappini, B.; Occhini, U.; Birtolo, S.; Bosi, A.; Albano, F.; Fava, C.; Vannucchi, A.M.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

Leukemia Research
2011 | Journal article
EID:

2-s2.0-80051471275

Contributors: Latagliata, R.; Breccia, M.; Castagnetti, F.; Stagno, F.; Luciano, L.; Gozzini, A.; Ulisciani, S.; Cavazzini, F.; Annunziata, M.; Sorà, F. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib

Journal of the National Cancer Institute
2011 | Journal article
EID:

2-s2.0-79953880772

Contributors: Gambacorti-Passerini, C.; Antolini, L.; Mahon, F.-X.; Guilhot, F.; Deininger, M.; Fava, C.; Nagler, A.; Della Casa, C.M.; Morra, E.; Abruzzese, E. et al.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Can We and Should We Improve on Frontline Imatinib Therapy for Chronic Myeloid Leukemia?

Seminars in Hematology
2010 | Journal article
EID:

2-s2.0-77957036311

Contributors: Fava, C.; Saglio, G.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

British Journal of Haematology
2010 | Journal article
EID:

2-s2.0-77954612906

Contributors: Santos, F.P.S.; Kantarjian, H.; Fava, C.; O'Brien, S.; Garcia-Manero, G.; Ravandi, F.; Wierda, W.; Thomas, D.; Shan, J.; Cortes, J.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution

Cancer Genetics and Cytogenetics
2010 | Journal article
EID:

2-s2.0-77952754828

Contributors: Falchi, L.; Rege-Cambrin, G.; Fava, C.; Donti, E.; Luzi, D.; Giugliano, E.; Gubbiotti, M.; Schippa, M.; Liberati, A.M.
Source: Self-asserted source
carmen fava via Scopus - Elsevier

Advances in the biology and therapy of patients with chronic myeloid leukaemia

Best Practice and Research: Clinical Haematology
2009 | Journal article
EID:

2-s2.0-71849103177

Contributors: Jabbour, E.; Fava, C.; Kantarjian, H.
Source: Self-asserted source
carmen fava via Scopus - Elsevier
Items per page:
Page 1 of 2